Last reviewed · How we verify
Xiyanping injection plus western therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Xiyanping injection plus western therapy (Xiyanping injection plus western therapy) — Jiangxi Qingfeng Pharmaceutical Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Xiyanping injection plus western therapy TARGET | Xiyanping injection plus western therapy | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Xiyanping injection plus western therapy CI watch — RSS
- Xiyanping injection plus western therapy CI watch — Atom
- Xiyanping injection plus western therapy CI watch — JSON
- Xiyanping injection plus western therapy alone — RSS
Cite this brief
Drug Landscape (2026). Xiyanping injection plus western therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/xiyanping-injection-plus-western-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab